Angiogenesis Inhibitors: all 4,430 studies that test it
Page 3 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
- Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain MetastasesRecruitingNCT06888817Phase 3
- CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal CancerRecruitingNCT06881537Phase 2
- The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in AdultsNot yet recruitingNCT06876701Early Phase 1
- Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment IntervalsRecruitingNCT06875245Phase 4
- Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal CancerNot yet recruitingNCT06872606Phase 2
- SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II TrialRecruitingNCT06863584Phase 2
- Aflibercept and Bevacizumab for Diabetic MaculopathiesRecruitingNCT06850571Phase 4
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDRecruitingNCT06847542Phase 3
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingNCT06843447Phase 1/2
- Phase 1/2 Study of IMC-R117C in Selected Advanced CancersRecruitingNCT06840119Phase 1/2
- SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.Not yet recruitingNCT06835179Phase 2
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingNCT06820463Phase 2
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingNCT06803693Phase 2
- First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerRecruitingNCT06799065Phase 1/2
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)RecruitingNCT06796907Phase 1/2
- Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary DiseaseRecruitingNCT06793475Not applicable
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingNCT06793189Phase 2
- HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingNCT06792825Phase 2
- Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRRecruitingNCT06790784Phase 3
- The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)RecruitingNCT06789757Phase 2
- PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLMRecruitingNCT06788171Phase 2
- QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCRecruitingNCT06786026Phase 2
- Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LVRecruitingNCT06782685Phase 1/2
- A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLCRecruitingNCT06775275Phase 2
- Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)Not yet recruitingNCT06772480Not applicable
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingNCT06769425Phase 1
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
- Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.RecruitingNCT06762431Phase 1/2
- Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymRecruitingNCT06760156Phase 2
- Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expressionRecruitingNCT06749860Phase 2
- Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the BrainRecruitingNCT06747728Not applicable
- Hop Compounds on the Immune System in Overweight PeopleRecruitingNCT06745102Not applicable
- PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCCRecruitingNCT06742424Phase 2
- Faricimab Quarterly Maintenance for Neovascular Age Related Macular DegenerationRecruitingNCT06742307Phase 4
- Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerRecruitingNCT06735326Phase 2
- Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaRecruitingNCT06723457Phase 2
- Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingNCT06718933Phase 1/2
- Interleukin23 in Systemic LupusRecruitingNCT06713187Not applicable
- Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)RecruitingNCT06709339Phase 4
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)RecruitingNCT06703073Phase 2
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: BevacizumabRecruitingNCT06701656Phase 2
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal CancerRecruitingNCT06696768Phase 1
- SHR-1701 Combined with SHR2554 and BP102 for MCRCNot yet recruitingNCT06679673Phase 2
- Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesRecruitingNCT06675136Phase 1
- Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLCRecruitingNCT06663306Phase 1
- High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyRecruitingNCT06662994Phase 4
- NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
- Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line TreatmentRecruitingNCT06642844Phase 3
- Local Injection and Systemic Therapy in the Treatment of NSCLC.Not yet recruitingNCT06618391Phase 2
- Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.RecruitingNCT06617936Phase 2
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.RecruitingNCT06617182Phase 2
- GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPCNot yet recruitingNCT06611826Phase 2
- Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral CurcuminRecruitingNCT06595355Phase 2/3
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerRecruitingNCT06580314Phase 3
- Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginRecruitingNCT06576037Phase 1
- Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO PatientsRecruitingNCT06572553Phase 2/3
- A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver MetastasisNot yet recruitingNCT06564298Phase 2
- CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLCNot yet recruitingNCT06557096Early Phase 1
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
- Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Not yet recruitingNCT06549335Phase 2
- External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerRecruitingNCT06543576Phase 1/2
- Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMRecruitingNCT06543069Phase 2
- Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or CetuximabRecruitingNCT06540326Phase 2
- Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerNot yet recruitingNCT06539559Phase 2
- Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal MetastasesNot yet recruitingNCT06537297Phase 2
- Thalidomide for the Symptomatic Large Granular Lymphocytic LeukemiaRecruitingNCT06530576Phase 2
- The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Phase 3
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
- A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With AdebrelimabNot yet recruitingNCT06513221Phase 2
- A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsRecruitingNCT06497985Phase 3
- Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2
- Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
- First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal CancerNot yet recruitingNCT06491355Phase 2
- Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta ThalassemiaRecruitingNCT06490627Phase 2
- Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal MetastasisEnrolling by invitationNCT06487715Phase 2
- Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain MetastasesRecruitingNCT06471465Phase 3
- A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRecruitingNCT06469281Phase 1
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaRecruitingNCT06461988Phase 2
- Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT06459687Phase 3
- Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyRecruitingNCT06455748Not applicable
- Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
- Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingNCT06446206Phase 2
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingNCT06445972Phase 1/2
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
- Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionRecruitingNCT06439485Phase 1/2
- Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal CancerNot yet recruitingNCT06434090Phase 1/2
- The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant AscitesRecruitingNCT06433869Phase 2
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Phase 1/2
- MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRecruitingNCT06414148Phase 2
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
- Daratumumab for Patients With Light Chain AmyloidosisRecruitingNCT06376214Not applicable
- SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal CancerNot yet recruitingNCT06373133Phase 1/2
- Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal CarcinomaNot yet recruitingNCT06364826Phase 2
- A Study of SC-0191 in Subjects With Metastatic Colorectal CancerNot yet recruitingNCT06363552Phase 2
- SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain MetastasesNot yet recruitingNCT06361979Phase 2
- Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2